{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhou Z"],"funding":["Natural Science Foundation of Hunan Province","Youth Science Foundation of Xiangya Hospital","National Natural Science Foundation of China","National Nature Science Foundation of China","Natural Science Foundation of Changsha","The China Postdoctoral Science Foundation"],"pagination":["1647-1656"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11098653"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(3)"],"pubmed_abstract":["<h4>Aims</h4>The study aims to provide comprehensive evidence for the selection of agents in type 2 diabetes mellitus (T2DM) patients with cardiovascular risk and summarize the lasted evidence for the cardiovascular effects of sodium glucose cotransporter-2 inhibitor (SGLT2i) in patients with heart failure (HF).<h4>Methods and results</h4>Several online databases were searched. All studies that explored the cardiovascular effects of SGLT2i or glucagon-like peptide 1 receptor agonist (GLP1-RA) were screened and reviewed. A total of 38 studies were included. Compared with GLP1-RA, the use of SGLT2i significantly reduced the risk of cardiovascular death [risk ratio (RR) = 0.59; 95% confidence interval (CI), 0.44-0.58], hospitalization of heart failure (HHF) (RR = 0.77; 95% CI, 0.74-0.80), dea"],"journal":["ESC heart failure"],"pubmed_title":["Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis."],"pmcid":["PMC11098653"],"funding_grant_id":["2023M733963","82300490","2023JJ40996","2022Q01","kq2208369"],"pubmed_authors":["Zuo Z","Zheng M","Wu T","Zhou Z"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis.","description":"<h4>Aims</h4>The study aims to provide comprehensive evidence for the selection of agents in type 2 diabetes mellitus (T2DM) patients with cardiovascular risk and summarize the lasted evidence for the cardiovascular effects of sodium glucose cotransporter-2 inhibitor (SGLT2i) in patients with heart failure (HF).<h4>Methods and results</h4>Several online databases were searched. All studies that explored the cardiovascular effects of SGLT2i or glucagon-like peptide 1 receptor agonist (GLP1-RA) were screened and reviewed. A total of 38 studies were included. Compared with GLP1-RA, the use of SGLT2i significantly reduced the risk of cardiovascular death [risk ratio (RR) = 0.59; 95% confidence interval (CI), 0.44-0.58], hospitalization of heart failure (HHF) (RR = 0.77; 95% CI, 0.74-0.80), dea","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-07-15T02:00:53.829Z","creation":"2026-06-27T03:17:18.208Z"},"accession":"S-EPMC11098653","cross_references":{"pubmed":["38419382"],"doi":["10.1002/ehf2.14726"]}}